

Note: This document has been translated from the Japanese original for reference purposes only. In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.

November 14, 2025

Consolidated Financial Results for the Six Months Ended September 30, 2025 (Under Japanese GAAP)



Company name: Menicon Co., Ltd.

Listing: Tokyo Stock Exchange, Nagoya Stock Exchange

Securities code: 7780

URL: <https://www.menicon.com>

Representative: Koji Kawaura

President and CEO

Inquiries: Hideki Koga

Senior Executive Officer, Corporate Management, CFO

Telephone: +81-52-935-1515

Scheduled date to file semi-annual securities report: November 14, 2025

Scheduled date to commence dividend payments: -

Preparation of supplementary material on financial results: Yes

Holding of financial results briefing: Yes

(Yen amounts are rounded down to millions, unless otherwise noted.)

1. Consolidated financial results for the six months ended September 30, 2025 (from April 1, 2025 to September 30, 2025)

(1) Consolidated operating results (cumulative)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Six months ended September 30, 2025	61,480	1.5	5,168	(5.8)	5,016	(10.7)	3,153	(12.9)
September 30, 2024	60,571	4.2	5,487	4.5	5,618	13.4	3,622	9.0

Note: Comprehensive income For the six months ended September 30, 2025: ¥ 4,783 million [(25.5) %]
For the six months ended September 30, 2024: ¥ 6,423 million [3.4 %]

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Six months ended September 30, 2025	41.81	41.61
September 30, 2024	47.67	43.96

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
	Millions of yen	Millions of yen	%
As of September 30, 2025	187,064	86,557	45.9
March 31, 2025	187,590	86,129	45.4

Reference: Equity

As of September 30, 2025: ¥ 85,830 million

As of March 31, 2025: ¥ 85,211 million

(Note) During the second quarter of the fiscal year ending March 31, 2026, we finalized the provisional accounting treatment for a business combination. Accordingly, the finalized figures have been retrospectively reflected in the results for the fiscal year ended March 31, 2025.

2. Cash dividends

	Annual dividends per share				
	First quarter-end	Second quarter-end	Third quarter-end	Fiscal year-end	Total
	Yen	Yen	Yen	Yen	Yen
Fiscal year ended March 31, 2025	-	0.00	-	28.00	28.00
Fiscal year ending March 31, 2026	-	0.00			
Fiscal year ending March 31, 2026 (Forecast)			-	28.00	28.00

Note: Revisions to the forecast of cash dividends most recently announced: None

3. Consolidated financial result forecasts for the fiscal year ending March 31, 2026 (from April 1, 2025 to March 31, 2026)

(Percentages indicate year-on-year changes.)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent		Basic earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
Full year	125,000	2.9	10,200	1.9	9,500	(0.7)	5,800	3.6	77.57

Note:

- Revision to the financial results forecast announced most recently: None
- Basic earnings per share for the consolidated financial results forecast for the fiscal year ending March 31, 2026 have been calculated using the average number of shares outstanding during the period, reflecting the treasury share purchases.

* Notes

- Significant changes in the scope of consolidation during the period: Yes

Newly included:	-	companies(	)
Excluded:	1	company(Oculus Visioncare (S) Pte. Ltd.	)

- Adoption of accounting treatment specific to the preparation of semi-annual consolidated financial statements: Yes

- Changes in accounting policies, changes in accounting estimates, and restatement

- Changes in accounting policies due to revisions to accounting standards and other regulations: None
- Changes in accounting policies due to other reasons: Yes
- Changes in accounting estimates: None
- Restatement: None

- Number of issued shares (common shares)

- Total number of issued shares at the end of the period (including treasury shares)

As of September 30, 2025	76,756,888 shares
As of March 31, 2025	76,645,888 shares

- Number of treasury shares at the end of the period

As of September 30, 2025	2,636,924 shares
As of March 31, 2025	714,024 shares

- Average number of shares outstanding during the period (cumulative from the beginning of the fiscal year)

Six months ended September 30, 2025	75,411,816 shares
Six months ended September 30, 2024	75,985,694 shares

- (Note) The Company's shares held by "Employee Stock Ownership Plan (Stock Benefit Trust)" and the "Stock Benefit Trust (Employee Shareholder Association Purchase-Type)" are included in treasury shares, which are used in calculating the total number of treasury shares at the end of the period and deducted in calculating the average number of shares during the period.

* Semi-annual financial results reports are exempt from review conducted by certified public accountants or an audit firm.

* Proper use of earnings forecasts, and other special matters

- Forecasts regarding future performance presented in this material include the outlook for the future, assumptions on which the plan is based, and projections as of the date of announcement of this material. Actual results may differ from the forecasts presented in this material due to various factors.
- For matters concerning the forecast of business results, please refer to “1. Qualitative Information on Semi-annual Financial Results for the Period under Review (3) Explanation of Consolidated Business Results Forecast and Other Forward-looking Information” on Page 4 of the appendix.

Table of contents of appendix

1. Qualitative Information on Semi-annual Financial Results for the Period under Review.....	2
(1) Explanation of Business Results	2
(2) Explanation of Financial Position	3
(3) Explanation of Consolidated Financial Results Forecast and Other Forward-looking Information	4
2. Semi-annual Consolidated Financial Statements and Notes.....	5
(1) Semi-annual Consolidated Balance Sheet.....	5
(2) Semi-annual Consolidated Statements of Income and Comprehensive Income	7
Semi-annual Consolidated Statement of Income (For the six months ended September 30).....	7
Semi-annual Consolidated Statement of Comprehensive Income (For the six months ended September 30).....	8
(3) Semi-annual Consolidated Statement of Cash Flows	9
(4) Notes to Semi-annual Consolidated Financial Statements.....	10
Going concern assumption.....	10
Significant changes in amount of shareholders' equity.....	10
Application of Special Accounting Treatments for Preparing Semi-annual Consolidated Financial Statements	10
Changes in accounting policies	10
Additional information.....	11
Segment information.....	12
Significant subsequent events	14

1. Qualitative Information on Semi-annual Financial Results for the Period under Review

(1) Explanation of Business Results

We established the current Medium-term Management Plan, “Vision 2030” and are promoting a “1-DAY lens Strategic Policy: Aim to be a top global player in 1-DAY lens with original products and services” and an “Orthokeratology-related (Myopia Control-related) Strategy: Aim to be the leading company in orthokeratology-related (Myopia Control-related) business by creating new value related to myopia control” as growth strategy policies to realize “New Vision of ‘Miru’ for the world.”

Performances in each business are as follows.

[Vision Care Business]

Regarding the “1-DAY lens Strategy,” the global contact lens market is experiencing rising demand for daily disposable contact lenses made of highly safe silicone hydrogel materials due to the rising myopic population.

In Japan, we aim to increase the proportion of daily disposable contact lenses among MELS Plan members. Overseas, we are working to expand sales by strengthening business relationships with major retail chains. To meet increasing demand, we are enhancing production capacity not only at the Kakamigahara Plant and Menicon Singapore Pte. Ltd., but also at our new production base, Menicon Malaysia Sdn. Bhd.

During the six months ended September 30, 2025, we implemented price revisions for certain products in Japan to ensure the stable supply of products and the consistent provision of services. Regarding daily disposable contact lenses, for which we are expanding production capacity, OEM products were introduced to meet current demand. We began sales of the “1DAY Menicon MelsME” as an exclusive product for the MELS Plan, and the “1DAY Menicon DearTEAR” as a product for the retail market. In Europe, we worked to expand sales by broadening our product line-up at major retail chains we currently do business with. In China, we strengthened promotional activities for products from our Group companies through one of the largest online contact lens retailers in the country, aiming to expand net sales.

Regarding the Orthokeratology-related (Myopia Control-related) Strategy, we have worked to strengthen sales of orthokeratology lenses and their associated care products in China. However, the orthokeratology-related market there remains stagnant due to declining consumer purchasing power amid the economic downturn and the emergence of alternative products, while competition in the care products market has intensified. In contrast, demand is expanding in Japan and other Asian countries and looks set to grow further going forward.

We will aim to expand sales globally through efforts such as increasing the recognition of lens products in conjunction with care products and developing new sales channels, by leveraging a line-up of multiple orthokeratology lenses, including “Alpha Ortho-K,” (marketed as “Menicon Ortho-K” in Japan) which is enjoying strong sales in Japan and the rest of Asia, “Menicon Z Night,” which is experiencing robust sales in Europe and Asia, and “Menicon Bloom Night,” a contact lens with a CE Mark certification for myopia control, which is expected to see sales expansion in Europe and elsewhere.

During the six months ended September 30, 2025, we worked in China to promote sales of orthokeratology lenses and related lens care products through sustained promotional support for sales channels, exhibitions at academic conferences, and consumer engagement activities in cooperation with leading physicians in the field of orthokeratology. In India, we obtained medical device import approval for orthokeratology lenses and proceeded with preparations for their future launch.

[Other Business]

The Healthcare and Life Care business is pursuing the challenge to enter new fields that create health support and joy for people through the five senses. Key focus areas are; the healthcare field, particularly femtech including fertility treatments; the Life Care field, with emphasis on environmental initiatives; Veterinary Medical business supporting pet life; and the Food business, which involves the sale and import/export of agricultural and marine products.

During the six-months ended September 30, 2025, our composting-related business in the life care field contributed to sales growth by expanding sales channels through continued marketing efforts. In the Veterinary Medical business, we have expanded our product lineup of intraocular lenses for dogs and are currently preparing for the launch of sales.

As the result, our consolidated business results for the six months ended September 30, 2025 were as follows:

Net sales increased by 1.5% year on year to ¥61,480 million, reflecting the effect of price revisions in Japan, the expansion of sales of daily disposable contact lenses both in Japan and overseas, and the contribution from the acquisition of Oculus (M) Sdn. Bhd. and two other sales companies in Southeast Asia during the previous consolidated fiscal year. Operating profit decreased by 5.8% year on year to ¥5,168 million, primarily reflecting an increase in investments and expenses for future growth, including preparations for the operation of a new plant and wage increases for employees. Ordinary profit decreased by 10.7% year on year to ¥5,016 million, reflecting the recognition of foreign exchange losses (compared with foreign exchange gains in the previous period).

Consequently, profit attributable to owners of parent decreased by 12.9% year on year to ¥3,153 million.

Business results by segment are as follows:

1) Vision Care Business

Net sales in the Vision Care Business amounted to ¥57,278 million, a 1.7% increase year on year, while segment profit decreased by 6.9% year on year to ¥8,299 million. Details are as follows.

Net sales in the Vision Care Business increased by ¥983 million year on year.

Net sales of daily disposable contact lenses increased by ¥1,108 million, reflecting the effect of price revisions in Japan, the increase in the number of MELS Plan members using these lenses, higher product sales volumes in Japan, and expanded sales to major retail chains in Europe.

Net sales of Orthokeratology-related products decreased by ¥856 million, despite steady demand in Japan, reflecting the economic slowdown in China, intensified competition, and the growing prevalence of alternative products.

Net sales of other contact lens-related products increased, reflecting the effect of price revisions and expanded sales of monthly replacement contact lenses in Europe.

Segment profit decreased by ¥612 million year on year, reflecting increased investments and expenses for future growth, including preparations for plant operations and wage increases for employees.

2) Other

Net sales in Other Businesses amounted to ¥4,202 million, a 1.7% decrease year on year, as the increase in sales from the composting-related business was offset by the contraction of the food business in China. The segment loss improved to ¥194 million (compared with a segment loss of ¥540 million in the same period of the previous year), reflecting improved profitability following the withdrawal from certain businesses and reduction in selling, general and administrative expenses.

(2) Explanation of Financial Position

During the six months ended September 30, 2025, the provisional accounting treatment for a business combination was finalized. Accordingly, the revised figures reflecting this finalized treatment have been used for comparison and analysis with the previous consolidated fiscal year.

(Assets)

Total assets as of the end of the six-months period ended September 30, 2025 amounted to ¥187,064 million, a decrease of ¥526 million from the end of the previous fiscal year. Current assets decreased by ¥4,607 million to ¥78,061 million, reflecting a decline in cash and deposits resulting from capital expenditures, the acquisition of treasury shares, and dividend payments. Non-current assets increased by ¥4,081 million to ¥109,002 million, reflecting investments related to the construction of manufacturing facilities for daily disposable contact lenses at Menicon Malaysia Sdn. Bhd.

(Liabilities and Net Assets)

Total liabilities decreased by ¥953 million from the end of the previous fiscal year to ¥100,507 million, reflecting a decrease in other accounts payable associated with payments for capital investment in manufacturing facilities at Menicon Malaysia Sdn. Bhd., despite the increase in short-term borrowings.

Total net assets increased by ¥427 million to ¥86,557 million, primarily due to the recognition of profit attributable to owners of parent for the six months ended September 30, 2025 and an increase in foreign currency translation adjustments related to overseas subsidiaries as a result of the depreciation of the yen, despite the acquisition of treasury shares.

As a result, the equity ratio was 45.9%.

(Status of Cash Flows)

Cash and cash equivalents at the end of the six months ended September 30, 2025 decreased by ¥6,220 million from the end of the previous consolidated fiscal year to ¥35,643 million, representing a 14.9% decrease year on year.

(Cash Flows from Operating Activities)

Net cash provided by operating activities amounted to an inflow of ¥6,260 million (compared to an inflow of ¥5,195 million in the same period of the previous fiscal year), reflecting income before income taxes and depreciation.

(Cash Flows from Investing Activities)

Net cash used in investing activities amounted to an outflow of ¥9,500 million (compared to an outflow of ¥11,682 million in the same period of the previous fiscal year), reflecting capital investment in manufacturing facilities for daily disposable contact lenses at Menicon Malaysia Sdn. Bhd. and capital investment in contact lens manufacturing facilities at the Company.

(Cash Flows from Financing Activities)

Net cash used in financing activities amounted to an outflow of ¥3,034 million (compared to an outflow of ¥787 million in the same period of the previous fiscal year), reflecting share buybacks and dividend payments, despite an increase in short-term borrowings.

(3) Explanation of Consolidated Financial Results Forecast and Forward-looking Information

For the six months ended September 30, 2025 (the second quarter of the fiscal year ending March 31, 2026), consolidated results remained generally steady compared with the full-year consolidated earnings forecast for the fiscal year, reflecting the positive effect of price revisions for certain products in Japan, as well as sales growth of daily disposable contact lenses. This growth was supported by the increase in MELS Plan members through the introduction of OEM products, expansion of domestic sales, and higher sales volume to major retail chains in Europe.

From the third quarter onward, we expect continued revenue growth driven by the ongoing effect of price revisions, the utilization of OEM products in Japan, and enhanced production capacity to expand supply of daily disposable contact lenses. Overseas, sales to major retail chains are also expected to grow.

Accordingly, there are no revisions to the full-year consolidated earnings forecast for the fiscal year ending March 31, 2026, announced on May 14, 2025.

2. Semi-annual Consolidated Financial Statements and Notes

(1) Semi-annual Consolidated Balance Sheets

(Millions of yen)

	As of March 31, 2025	As of September 30, 2025
Assets		
Current assets		
Cash and deposits	42,046	35,827
Notes and accounts receivable - trade	13,641	14,294
Merchandise and finished goods	15,709	16,669
Work in process	1,464	1,670
Raw materials and supplies	4,045	4,190
Other	6,236	5,903
Allowance for doubtful accounts	(473)	(493)
Total current assets	82,669	78,061
Non-current assets		
Property, plant and equipment		
Buildings and structures	58,419	59,266
Accumulated depreciation	(15,722)	(16,715)
Buildings and structures, net	42,697	42,551
Machinery, equipment and vehicles	28,994	31,596
Accumulated depreciation	(19,251)	(20,406)
Machinery, equipment and vehicles, net	9,743	11,189
Tools, furniture and fixtures	11,992	12,560
Accumulated depreciation	(9,584)	(10,060)
Tools, furniture and fixtures, net	2,407	2,499
Land	5,656	5,690
Leased assets	6,008	6,008
Accumulated depreciation	(1,346)	(1,628)
Leased assets, net	4,662	4,380
Right of use assets	8,717	8,961
Accumulated depreciation	(5,057)	(5,613)
Right of use assets, net	3,660	3,347
Construction in progress	14,190	18,375
Other	46	46
Accumulated depreciation	-	-
Other, net	46	46
Total property, plant and equipment	83,064	88,080
Intangible assets		
Goodwill	3,227	2,958
Other	12,367	11,778
Total intangible assets	15,595	14,737
Investments and other assets		
Investment securities	822	1,009
Deferred tax assets	2,839	2,721
Other	3,142	2,956
Allowance for doubtful accounts	(542)	(502)
Total investments and other assets	6,261	6,184
Total non-current assets	104,921	109,002
Total assets	187,590	187,064

(Millions of yen)

	As of March 31, 2025	As of September 30, 2025
Liabilities		
Current liabilities		
Notes and accounts payable - trade	6,419	6,016
Short-term borrowings	25	3,251
Current portion of bonds payable	166	166
Current portion of long-term borrowings	978	1,375
Lease liabilities	2,064	2,075
Accounts payable - other	7,381	4,202
Income taxes payable	1,918	1,907
Provision for bonuses	2,107	2,410
Provision for point card certificates	32	43
Other	5,398	6,215
Total current liabilities	26,492	27,666
Non-current liabilities		
Bonds payable	46,167	46,083
Long-term borrowings	19,213	18,078
Lease liabilities	6,476	5,699
Retirement benefit liability	629	669
Deferred tax liabilities	1,534	1,476
Asset retirement obligations	110	111
Other	836	722
Total non-current liabilities	74,968	72,840
Total liabilities	101,460	100,507
Net assets		
Shareholders' equity		
Share capital	5,535	5,642
Capital surplus	7,558	7,665
Retained earnings	64,456	65,463
Treasury shares	(928)	(3,159)
Total shareholders' equity	76,621	75,611
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	362	490
Foreign currency translation adjustment	8,227	9,728
Total accumulated other comprehensive income	8,590	10,218
Share acquisition rights	859	666
Non-controlling interests	57	60
Total net assets	86,129	86,557
Total liabilities and net assets	187,590	187,064

(2) Semi-annual Consolidated Statements of Income and Comprehensive Income

Semi-annual Consolidated Statements of Income (For the six months ended September 30)

(Millions of yen)

	For the six months ended September 30, 2024	For the six months ended September 30, 2025
Net sales	60,571	61,480
Cost of sales	27,770	28,205
Gross profit	32,801	33,275
Selling, general and administrative expenses	27,313	28,106
Operating profit	5,487	5,168
Non-operating income		
Interest income	60	76
Dividend income	9	14
Foreign exchange gains	272	-
Insurance contract change gain	-	70
Other	154	189
Total non-operating income	496	351
Non-operating expenses		
Interest expenses	303	405
Share of loss of entities accounted for using equity method	9	-
Foreign exchange losses	-	13
Other	52	84
Total non-operating expenses	365	503
Ordinary profit	5,618	5,016
Extraordinary income		
Gain on sale of non-current assets	2	2
Reversal of foreign currency translation adjustment	-	15
Total extraordinary income	2	17
Extraordinary losses		
Loss on retirement of non-current assets	53	27
Total extraordinary losses	53	27
Profit before income taxes	5,568	5,005
Income taxes current	1,944	1,851
Profit	3,623	3,154
Profit attributable to non-controlling interests	1	1
Profit attributable to owners of parent	3,622	3,153

Semi-annual Consolidated Statements of Comprehensive Income (For the six months ended September 30)

(Millions of yen)

	For the six months ended September 30, 2024	For the six months ended September 30, 2025
Profit	3,623	3,154
Other comprehensive income		
Valuation difference on available-for-sale securities	(26)	127
Deferred gains or losses on hedges	(4)	-
Foreign currency translation adjustment	2,830	1,501
Share of other comprehensive income of entities accounted for using equity method	0	-
Total other comprehensive income	2,800	1,629
Comprehensive income	6,423	4,783
Comprehensive income attributable to		
Comprehensive income attributable to owners of parent	6,422	4,781
Comprehensive income attributable to non-controlling interests	1	2

(3) Semi-annual Consolidated Statements of Cash Flows

(Millions of yen)

	For the six months ended September 30, 2024	For the six months ended September 30, 2025
Cash flows from operating activities		
Profit before income taxes	5,568	5,005
Depreciation	3,737	4,536
Amortization of goodwill	230	297
Interest and dividend income	(70)	(91)
Interest expenses	303	405
Foreign exchange losses (gains)	(24)	118
Decrease (increase) in trade receivables	(480)	(376)
Decrease (increase) in inventories	(891)	(1,443)
Increase (decrease) in trade payables	(807)	(442)
Increase (decrease) in accounts payable - other	(243)	(950)
Increase (decrease) in provision for bonuses	(88)	299
Other, net	(496)	1,072
Subtotal	6,737	8,431
Interest and dividends received	64	80
Interest paid	(288)	(397)
Income taxes paid	(1,317)	(1,854)
Net cash provided by (used in) operating activities	5,195	6,260
Cash flows from investing activities		
Purchase of intangible assets	(1,375)	(639)
Purchase of property, plant and equipment	(8,155)	(8,997)
Proceeds from sale of property, plant and equipment	0	1
Purchase of shares of subsidiaries resulting in change in scope of consolidation	(2,066)	-
Other, net	(85)	134
Net cash provided by (used in) investing activities	(11,682)	(9,500)
Cash flows from financing activities		
Net increase (decrease) in short-term borrowings	(101)	3,223
Proceeds from long-term borrowings	1,140	-
Repayments of long-term borrowings	(1,166)	(738)
Redemption of bonds	(83)	(83)
Purchase of treasury shares	(1,140)	(2,399)
Proceeds from sale of treasury shares	654	171
Proceeds from sale and leaseback transactions	2,810	-
Repayments of lease liabilities	(997)	(1,063)
Dividends paid	(1,903)	(2,144)
Other, net	0	0
Net cash provided by (used in) financing activities	(787)	(3,034)
Effect of exchange rate change on cash and cash equivalents	846	53
Net increase (decrease) in cash and cash equivalents	(6,428)	(6,220)
Cash and cash equivalents at beginning of period	46,713	41,864
Cash and cash equivalents at end of period	40,285	35,643

(4) Notes to Semi-annual Consolidated Financial Statements

Going concern assumption

Not applicable.

Significant changes in amount of shareholders' equity

We acquired 2,052,900 shares of treasury stock based on the resolution of the Board of Directors meeting held on June 19, 2025. As the result of this acquisition and related transactions during the six months ended September 30, 2025, the balance of treasury stock increased by ¥2,230 million, bringing the total balance to ¥3,159 million as of the end of the six months ended September 30, 2025.

Application of Special Accounting Treatments for Preparing Semi-annual Consolidated Financial Statements

(Calculation of tax expenses)

Tax expenses are calculated by reasonably estimating the effective tax rate after applying tax-effect accounting to profit before income taxes for the full fiscal year including the semi-annual period under review, and multiplying profit before income taxes by the estimated effective tax rate. However, for companies where applying the estimated effective tax rate would lead to a significantly unreasonable outcome, the statutory effective tax rate is used instead, taking into account material additions and subtractions.

Changes in accounting policies

(Changes in the calculation method of tax expenses)

Previously, tax expenses were calculated using the principle-based method. However, to further improve efficiency in semi-annual settlement procedures, tax expenses are now presented under "Application of Special Accounting Treatments for Preparing Semi-annual Consolidated Financial Statements" from the semi-annual period under review. As the impact of this change is insignificant, it has not been applied retrospectively.

Additional information

(Transaction to grant the Company's shares to employees, etc. through a trust)

We conducted transactions to grant the Company's shares to the Employee Shareholder Association through a trust with the purpose of enhancing employee benefits and providing incentives for improving the Company's corporate value.

1. Overview of Transaction

We reintroduced the Employee Stock Ownership Plan (Stock Benefit Trust; hereinafter, the "Plan") for the Employee Shareholder Association in June 2024. It is an employee incentive plan similar to the Stock Benefit Trust (Employee Shareholder Association Purchase-Type) introduced in September 2021.

The Plan is an employee benefit program designed mainly with reference to the Employee Stock Ownership Plan (ESOP), an employee compensation package widely used in the U.S. as part of an employee incentive plan, and the "Report on Company Stock Holding Schemes" released by the Ministry of Economy, Trade and Industry of Japan on November 17, 2008.

We will establish a trust in which members of the Shareholder Association who satisfy a certain set of requirements are beneficiaries, and the said trust will acquire the number of the Company's shares that the Shareholder Association is expected to acquire during the trust period within the predetermined share-acquisition period. Then, the trust will sell the Company's shares to the Shareholder Association on the same day every month. If the trust has generated profits due to a rise in share prices or otherwise at the time of expiration of the trust, cash will be distributed to employees who satisfy the beneficiary requirements. If, on the other hand, the trust incurred a loss on transfer due to a decline in share prices and a debt pertaining to trust assets remains, there will be no additional burden on the part of employees as we will pay off the outstanding loan balance en bloc to the bank pursuant to warranty provisions of the non-recourse loan agreement.

2. Residual Company's Shares Held in the Trust

The residual Company's shares held in the Trust are recorded at the book value in the trust (excluding incidental expenses) as treasury shares under net assets. The book value and number of shares of such treasury shares are ¥928 million and 713 thousand shares, respectively, for the previous fiscal year, and ¥759 million and 583 thousand shares, respectively, for the second quarter of the fiscal year under review.

3. Book Value of Borrowings Recorded Through the Application of Total Amount Method

¥938 million for the previous consolidated fiscal year, ¥751 million for the second quarter of the fiscal year under review

Segment information

For the six months ended September 30, 2024

1. Information on net sales and profit (loss) by reportable segment

(Millions of yen)

	Reportable segment		Others (Note)	Total
	Vision Care Business	Subtotal		
Net sales				
Net sales to external customers	56,295	56,295	4,276	60,571
Inter-segment net sales or transfers	—	—	0	0
Total	56,295	56,295	4,276	60,571
Segment profit (loss)	8,912	8,912	(540)	8,372

(Note) “Others” is a business segment not included in the reportable segment and includes the healthcare and life care businesses.

2. Differences between the total amount of profit or loss of the reportable segment and the amount stated in the consolidated statement of income, and major breakdown of such differences (Reconciliation)

(Millions of yen)

Profit	Amount
Reportable segment total	8,912
“Others” loss	(540)
Corporate expenses (Note)	(2,884)
Operating profit stated in the consolidated statement of income	5,487

(Note) Corporate expenses are mainly general and administrative expenses not attributable to the reportable segment.

3. Information on impairment loss of non-current assets, goodwill, etc. for the reportable segment

(Significant impairment loss on non-current assets)

Not applicable.

(Significant change in amount of goodwill)

Not applicable.

(Significant gain on bargain purchase)

Not applicable.

For the six months ended September 30, 2025

1. Information on net sales and profit (loss) by reportable segment

(Millions of yen)

	Reportable segment		Others (Note)	Total
	Vision Care Business	Subtotal		
Net sales				
Net sales to external customers	57,278	57,278	4,202	61,480
Inter-segment net sales or transfers	—	—	0	0
Total	57,278	57,278	4,202	61,481
Segment profit (loss)	8,299	8,299	(194)	8,105

(Note) “Others” is a business segment not included in the reportable segment and includes the healthcare and life care businesses.

2. Differences between the total amount of profit or loss of the reportable segment and the amount stated in the consolidated statement of income, and major breakdown of such differences (Reconciliation)

(Millions of yen)

Profit	Amount
Reportable segment total	8,299
“Others” loss	(194)
Corporate expenses (Note)	(2,936)
Operating profit stated in the consolidated statement of income	5,168

(Note) Corporate expenses are mainly general and administrative expenses not attributable to the reportable segment.

3. Information on impairment loss of non-current assets, goodwill, etc. for the reportable segment

(Significant impairment loss on non-current assets)

Not applicable.

(Significant change in amount of goodwill)

Not applicable.

(Significant gain on bargain purchase)

Not applicable.

Significant subsequent events

Not applicable.